Conferences
#ESHALL2019

International Conference
Acute Lymphoblastic Leukaemia

#ESHALL2019
Translational
May 17-19, 2019
-
Berlin, Germany

Chairs: Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzov

International Conference
Acute Lymphoblastic Leukaemia

Information

‍

ABOUT THE CONFERENCE:

Major advances have been reached recently in the knowledge of acute lymphoblastic leukaemia (ALL), including the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, identi­ cation of new potentially druggable disease subsets and discovery of predisposing preleukemic events. During the same period of time, progresses have been accomplished in the management of children and adults with ALL, thanks to routine monitoring of measurable residual disease (MRD), administration of intensi­ ed risk-adapted chemotherapy, introduction of targeted therapies and antibodies, followed by the remarkable eff­icacy of antibody-drug conjugates (ADCs), bi speci­fic T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has made ALL a fascinating disease, allowing major improvements in patients’ outcome, while providing important proofs of concept for the treatment of cancer in general.

The 1st ESH Translational Conference on ALL is designed to provide time and multiple opportunities for discussions and interactions with internationally recognized physicians and scientists in the ­field.

‍

SCIENTIFIC TOPICS:

• Master Pathways/Targets in B-Cell Precursor ALL
• Master Pathways/Targets In T-ALL
• Individual Management of ALL
• Immunotherapy for ALL
• Issues in Allogeneic Hsct
• Philadelphia Chromosome-Positive ALL
• T-Cell ALL/LL

‍

‍

‍

Programme

Read the final programme!

‍

CLICK HERE
ON-DEMAND CONTENT AVAILABLE
CLICK HERE

Corporate partners

With the support of*:

‍

Platinum Conference Partner
*******

‍

Level 1 Conference Partner
*******

‍

‍

Level 1 Conference Partner
*******

‍

‍

Level 1 Conference Partner
*******

‍

‍*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.

‍

Advancing haematology through international leading-edge disease- focused conferences.

Explore a portfolio of leading-edge scientific, translational research and clinically oriented meetings, designed to foster scientific exchange, practical insight, education and collaboration across clinical and research fields.
Explore all conferences